Seattle Genetics is a biotechnology company that is focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Its antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.
The Company also is advancing a deep pipeline of innovative therapies for blood cancers and solid tumors, including vadastuximab talirine (SGN-CD33A) an ADC in the pivotal phase 3 CASCADE clinical trial for acute myeloid leukemia (AML), enfortumab vedotin (ASG-22ME) for urothelial cancer under its collaboration with Astellas, and SGN-LIV1A for triple-negative breast cancer. Its programs are designed to address significant unmet medical needs and to improve treatment outcomes for patients.
Type | Public | |
Founded | 1998 | |
HQ | Bothell, WA, US | Map |
Website | seattlegenetics.com | |
Employee Ratings | ||
Overall Culture | A+ | More |
USD | |
---|---|
Revenue (FY, 2020) | 2.2b |
Gross profit (FY, 2020) | 2.0b |
Gross profit margin (FY, 2020), % | 90% |
Net income (FY, 2020) | 613.7m |
EBIT (FY, 2020) | 596.9m |
Market capitalization (24-Jun-2022) | 32.8b |
Closing stock price (24-Jun-2022) | 179.3 |
Cash (31-Dec-2020) | 558.4m |
EV | 32.3b |
USD | Q1, 2011 | Q2, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 48.2m | 34.7m | 33.7m | 57.3m | 73.6m | 71.0m | 68.3m | 68.3m | 75.9m | 82.2m | 77.1m | 84.1m | 111.2m | 95.4m | 106.3m | 109.1m | 108.2m | 135.3m | 140.6m | 170.2m | 169.4m | 195.2m | 218.4m | 213.3m | 234.5m | 240.5m | 267.5m | ||
Cost of goods sold | 3.1m | 3.0m | 2.7m | 3.2m | 3.3m | 3.5m | 3.7m | 4.1m | 4.7m | 5.2m | 5.9m | 6.6m | 5.9m | 6.9m | 7.4m | 7.5m | 8.1m | 9.0m | 10.4m | 48.2m | |||||||||
Gross profit | 45.2m | 31.7m | 30.9m | 54.2m | 70.2m | 67.4m | 64.6m | 64.2m | 71.1m | 76.9m | 71.2m | 77.4m | 105.2m | 88.5m | 98.9m | 101.7m | 100.2m | 126.3m | 130.2m | 192.2m | |||||||||
Gross profit Margin, % | 94% | 91% | 92% | 94% | 95% | 95% | 95% | 94% | 94% | 94% | 92% | 92% | 95% | 93% | 93% | 93% | 93% | 93% | 93% | 80% |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|
Cash | 87.6m | 54.7m | 64.1m | 56.9m | 102.3m | 108.7m | 160.9m | 78.2m | 274.6m | 558.4m |
Accounts Receivable | 55.0m | 33.4m | 29.5m | 39.2m | 52.9m | 61.9m | 84.8m | 146.3m | 236.0m | 325.0m |
Prepaid Expenses | 3.8m | 4.5m | 5.8m | 11.9m | 11.5m | 19.1m | 43.4m | 43.7m | 61.8m | |
Inventories | 9.5m | 849.0k | 27.1m | 43.5m | 57.0m | 68.1m | 60.0m | 53.2m | 85.9m | 116.1m |
USD | Q1, 2011 | Q2, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 61.5m | 79.8m | 53.3m | 60.8m | 54.9m | 34.9m | 27.6m | 119.5m | 44.8m | 38.8m | 50.2m | 62.6m | 79.0m | 614.1m | 119.5m | 192.1m | 131.0m | 75.8m | 197.1m | 128.1m | 186.9m | 159.3m | 115.5m | 84.3m | 64.1m | 193.5m | 249.1m | 117.3m | 919.5m |
Accounts Receivable | 8.6m | 11.0m | 56.6m | 31.6m | 35.2m | 44.7m | 47.7m | 29.2m | 37.9m | 34.9m | 43.8m | 49.6m | 45.3m | 63.5m | 52.4m | 57.7m | 65.1m | 73.7m | 71.9m | 90.4m | 118.6m | 150.0m | 152.5m | 157.0m | 182.3m | 190.3m | 224.6m | 290.1m | 293.4m |
Prepaid Expenses | 4.4m | 5.3m | 6.6m | 4.7m | 7.2m | 6.3m | 5.7m | 7.1m | 8.4m | 8.3m | 8.2m | 11.8m | 8.3m | 14.2m | 12.2m | 15.7m | 15.4m | 22.4m | 18.9m | 44.1m | 36.9m | 26.2m | 37.3m | 40.4m | 43.7m | 52.0m | 54.8m | 57.5m | |
Inventories | 15.8m | 25.7m | 429.0k | 1.1m | 1.2m | 26.0m | 29.0m | 30.5m | 37.5m | 43.1m | 47.5m | 44.5m | 60.1m | 71.7m | 71.6m | 60.7m | 69.2m | 60.8m | 71.9m | 70.9m | 75.2m | 67.2m | 73.2m | 92.0m | 84.7m | 90.0m | 96.7m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | (152.0m) | (53.8m) | (62.5m) | (76.1m) | (120.5m) | (140.1m) | (125.5m) | (222.7m) | (158.6m) | 613.7m |
Depreciation and Amortization | 4.2m | 6.2m | 8.6m | 12.5m | 14.5m | 18.0m | 24.3m | 26.0m | 23.8m | 36.0m |
Inventories | (9.5m) | (28.3m) | 10.7m | (16.4m) | (13.5m) | (11.2m) | 8.1m | 6.7m | (32.7m) | (30.2m) |
Accounts Payable | 27.3m | 3.1m | 1.5m | 18.4m | 6.5m | 29.9m | 19.1m | 33.1m |
USD | Q1, 2011 | Q2, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (32.7m) | (84.2m) | (12.3m) | (29.5m) | (43.2m) | (16.3m) | (23.2m) | (46.8m) | (16.3m) | (33.9m) | (49.5m) | (21.7m) | (69.2m) | (95.6m) | (20.5m) | (53.2m) | (85.0m) | (60.0m) | (116.3m) | (66.3m) | (111.7m) | (35.4m) | (102.9m) | (13.3m) | (92.6m) | (184.5m) | (168.4m) | (189.6m) | 446.6m |
Depreciation and Amortization | 875.0k | 1.8m | 1.5m | 3.0m | 4.6m | 1.7m | 3.8m | 6.1m | 2.8m | 5.9m | 9.1m | 3.4m | 7.0m | 10.8m | 4.2m | 8.6m | 13.3m | 4.8m | 10.2m | 16.4m | 7.0m | 13.8m | 19.0m | 4.9m | 9.9m | 14.1m | 6.0m | 16.6m | 36.8m |
Inventories | (6.3m) | (16.2m) | (24.8m) | 4.0m | (914.0k) | 11.7m | (2.0m) | (3.4m) | (10.5m) | 382.0k | (4.0m) | (1.1m) | (3.1m) | (14.7m) | (14.7m) | 7.4m | (1.1m) | 7.3m | (11.9m) | (11.0m) | (15.2m) | (14.0m) | (19.9m) | (38.8m) | 1.2m | (4.1m) | (10.8m) | ||
Accounts Payable | (390.0k) | 8.1m | (12.5m) | (894.0k) | (10.5m) | (10.4m) | (6.6m) | (2.7m) | (521.0k) | 3.4m | 10.1m | 3.1m | 9.1m | (633.0k) | (1.6m) | 6.5m | 8.4m | (18.5m) | (11.1m) | 6.2m | (28.9m) | (10.0m) | 2.2m |
USD | Q1, 2011 |
---|---|
Financial Leverage | 1.6 x |
Company Name | Date | Deal Size |
---|---|---|
Cascadian Therapeutics | January 31, 2018 | $614 m |
Seattle Genetics has 138 Twitter Followers. The number of followers has increased 1.6% month over month and increased 4.9% quarter over quarter
A+
91/100
A+
95/100
A+
96/100
When was Seattle Genetics founded?
Seattle Genetics was founded in 1998.
Who are Seattle Genetics key executives?
Seattle Genetics's key executives are Clay Siegall, Roger Dansey and Vaughn Himes.
How many employees does Seattle Genetics have?
Seattle Genetics has 1,605 employees.
What is Seattle Genetics revenue?
Latest Seattle Genetics annual revenue is $2.2 b.
What is Seattle Genetics revenue per employee?
Latest Seattle Genetics revenue per employee is $1.4 m.
Who are Seattle Genetics competitors?
Competitors of Seattle Genetics include Immunomedics, Memgen and Legend Biotech.
Where is Seattle Genetics headquarters?
Seattle Genetics headquarters is located at 21717 30th Dr SE Building 3, Bothell.
Where are Seattle Genetics offices?
Seattle Genetics has offices in Bothell, Mississauga, Hørsholm, Rueil-Malmaison and in 5 other locations.
How many offices does Seattle Genetics have?
Seattle Genetics has 10 offices.
Receive alerts for 300+ data fields across thousands of companies